Insulet (PODD) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.09% |
| Dec 31, 2025 | -20.49% |
| Sep 30, 2025 | -52.74% |
| Jun 30, 2025 | -18.07% |
| Mar 31, 2025 | 106.36% |
| Dec 31, 2024 | 17.92% |
| Sep 30, 2024 | -23.87% |
| Jun 30, 2024 | 57.21% |
| Mar 31, 2024 | 25.98% |
| Dec 31, 2023 | 27.13% |
| Sep 30, 2023 | 36.51% |
| Jun 30, 2023 | 18.76% |
| Mar 31, 2023 | 4.92% |
| Dec 31, 2022 | -18.19% |
| Sep 30, 2022 | -7.90% |
| Jun 30, 2022 | 21.56% |
| Mar 31, 2022 | -5.74% |
| Dec 31, 2021 | 4.09% |
| Sep 30, 2021 | -50.39% |
| Jun 30, 2021 | 24.42% |
| Mar 31, 2021 | -50.28% |
| Dec 31, 2020 | 40.22% |
| Sep 30, 2020 | 153.34% |
| Jun 30, 2020 | 314.81% |
| Mar 31, 2020 | -10.50% |
| Dec 31, 2019 | -114.54% |
| Sep 30, 2019 | 65.28% |
| Jun 30, 2019 | -18.24% |
| Mar 31, 2019 | 42.09% |
| Dec 31, 2018 | -23.41% |
| Sep 30, 2018 | -39.41% |
| Jun 30, 2018 | -90.54% |
| Mar 31, 2018 | -22.53% |
| Dec 31, 2017 | 97.05% |
| Sep 30, 2017 | 44.29% |
| Jun 30, 2017 | 26.55% |
| Mar 31, 2017 | -41.08% |
| Dec 31, 2016 | -51.28% |
| Sep 30, 2016 | 118.36% |
| Jun 30, 2016 | -78.12% |
| Mar 31, 2016 | -5.06% |
| Dec 31, 2015 | -34.68% |
| Sep 30, 2015 | 15.31% |